Summary:
Orange County Research Center is conducting a Multicenter, Randomized, Double-blind, Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheumatoid Arthritis.
Qualified Participants Must:
• Be 18 years of age or older
•
Have a diagnosis of RA with at least 8 tender or swollen joints
•
Have previous or current treatment with MTX and are considered intolerant to MTX, and/or are considered inappropriate for treatment with MTX, and/or an inadequate responder to MTX.
Qualified Participants May Receive:
Free medical care and treatment. Compensation for time and travel - $70.00 per visit